Sibutramine hydrochloride monohydrate

被引:17
作者
Oliveira, P. R. [1 ]
Stulzer, H. K. [2 ]
Bernardi, L. S. [1 ]
Borgmann, S. H. M. [1 ]
Cardoso, S. G. [1 ]
Silva, M. A. S. [1 ]
机构
[1] Univ Fed Santa Catarina, Hlth Sci Ctr, Dept Pharmaceut Sci, Qual Control Lab, BR-88040900 Florianopolis, SC, Brazil
[2] Univ Estadual Ponta Grossa, Dept Pharmaceut Sci, Qual Control Lab, BR-84010919 Ponta Grossa, PR, Brazil
关键词
Sibutramine; Thermal characterization; Kinetic studies; Compatibility studies; SOLID DOSAGE FORMS; THERMAL-ANALYSIS; NONISOTHERMAL CONDITIONS; DECOMPOSITION KINETICS; BINARY-MIXTURES; EXCIPIENTS; COMPATIBILITY; DSC; FORMULATIONS; BEHAVIOR;
D O I
10.1007/s10973-009-0200-7
中图分类号
O414.1 [热力学];
学科分类号
摘要
In the present work, the thermal decomposition of sibutramine hydrochloride monohydrate (SBT) (an appetite suppressant agent) was studied using differential scanning calorimetry (DSC) and thermogravimetry/derivative thermogravimetry (TG/DTG). Solid-state characterization was carried out by diffuse reflectance infrared fourier transform spectroscopy (DRIFT), scanning electron microscopy (SEM) and X-ray powder diffraction (XRPD). Isothermal and non-isothermal methods were employed to determine the kinetic data of decomposition process. From isothermal experiments, activation energy (Ea) can be obtained from slope of ln t versus 1/T, and the value obtained was 96.06 and 101.43 kJ mol(-1) in N(2) and air atmospheres, respectively. For non-isothermal method Ea can be obtained from plot of logarithms of heating rates, as a function of inverse of temperature, resulting in a value of 96.56 and 98.22 kJ mol(-1) in N(2) and air atmospheres, respectively. The compatibilities of several commonly used pharmaceutical excipients (microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, lactose monohydrate) and empty hard-gelatin capsules with SBT were evaluated using DSC. The 1:1 physical mixtures of these excipients with SBT showed physical interaction of the drug with magnesium stearate. On the other hand, DRIFT results did not evidence any chemical modifications.
引用
收藏
页码:277 / 282
页数:6
相关论文
共 50 条
  • [41] Near Infrared Spectroscopy Detection and Quantification of Herbal Medicines Adulterated with Sibutramine
    da Silva, Neirivaldo Cavalcante
    Honorato, Ricardo Saldanha
    Pimentel, Maria Fernanda
    Garrigues, Salvador
    Luisa Cervera, Maria
    de la Guardia, Miguel
    JOURNAL OF FORENSIC SCIENCES, 2015, 60 (05) : 1199 - 1205
  • [42] A Case of Sibutramine-induced hyperprolactinemia
    Soares Leaes, Carolina Garcia
    Semmelmann Pereira-Lima, Julia Fernanda
    Oliveira, Miriam da Costa
    NEUROENDOCRINOLOGY LETTERS, 2011, 32 (05) : 616 - 618
  • [43] When, for whom and how to use sibutramine?
    Astrup, A
    Toubro, S
    INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (Suppl 4) : S2 - S7
  • [44] Controversy about the Cardiovascular Safety of Sibutramine
    André J. Scheen
    Drug Safety, 2010, 33 : 615 - 618
  • [45] Metabolic benefits associated with sibutramine therapy
    Krejs G.J.
    International Journal of Obesity, 2002, 26 (Suppl 4) : S34 - S37
  • [46] Orlistat and sibutramine beyond weight toss
    Mannucci, Edoardo
    Dicembrini, Ilaria
    Rotella, Francesco
    Rotella, Carlo Maria
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2008, 18 (05) : 342 - 348
  • [47] Metabolic benefits associated with sibutramine therapy
    Krejs, QJ
    INTERNATIONAL JOURNAL OF OBESITY, 2002, 26 : S34 - S37
  • [49] Sibutramine in overweight/obese hypertensive patients
    AM Sharma
    International Journal of Obesity, 2001, 25 : S20 - S23
  • [50] Use of sibutramine in obese Hispanic adolescents
    Violante-Ortíz, R
    Del-Rio-Navarro, BE
    Lara-Esqueda, A
    Pérez, P
    Fanghänel, G
    Madero, A
    Berber, A
    ADVANCES IN THERAPY, 2005, 22 (06) : 642 - 649